FDA Twitter Ad Study Draws Drug Industry Comment

Leading drug firms and PhRMA have weighed in on the FDA’s plan to study the risks and benefits of online prescription drug communications and the possible impact of space limitations such as Twitter’s 140-character limit.

In a written comment, PhRMA said drug benefit claims could include a link to risk information and the group suggested that the FDA study how individuals use the character-space-limited platforms.

Eli Lilly noted that features such as Twitter cards on social media platforms extend Twitter’s 140-character limit and allow for additional information to be included.